Author:
Cheng Ying,Li Hui,Zhang Liang,Liu Jing-Jing,Yang Chang-Liang,Zhang Shuang
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
General Medicine,General Medicine
Reference83 articles.
1. Cancer statistics, 2017;Siegel;CA Cancer J Clin,2017
2. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer;Brahmer;N Engl J Med,2015
3. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial;Rittmeyer;Lancet,2017
4. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial;Herbst;Lancet,2016
5. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N Engl J Med,2015
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献